Pathophysiology of Benign Prostatic Hyperplasia: Insights From Medical Therapy for the Disease

Reviews in Urology

Herbert Lepor¹ 

[1] Department of Urology, New York University School of Medicine, New York, NY

关键词: α-Adrenoceptors;    α-Blockers;    Benign prostatic hyperplasia;    Bladder outlet obstruction;    Lower urinary tract symptoms;    Selectivity;   

DOI  :  

学科分类：基础医学

来源: MedReviews, LLC

【 摘 要 】

The medical treatment of benign prostatic hyperplasia (BPH) has its roots in the early 1970s. During this era, the first clinical trials investigating α-blockade and androgen deprivation therapy were reported for men with clinical BPH. The observation that clinical BPH was improved following administration of both α-blockers and androgen deprivation therapy supported the evolving paradigm that clinical BPH resulted from dynamic and static pathways. During the past several decades, the evolution of α-blockers for the treatment of BPH has been impacted by innovations targeted to simplify the administration and improve tolerability while maintaining their effectiveness.

【 授权许可】

Unknown